| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Tyk2 |
| Uniprot No | P29597 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 442-1187aa |
| 氨基酸序列 | RLVMSIRDGIHGPLLEPFVQAKLRPEDGLYLIHWSTSHPYRLILTVAQRSQAPDGMQSLRLRKFPIEQQDGAFVLEGWGRSFPSVRELGAALQGCLLRAGDDCFSLRRCCLPQPGETSNLIIMRGARASPRTLNLSQLSFHRVDQKEITQLSHLGQGTRTNVYEGRLRVEGSGDPEEGKMDDEDPLVPGRDRGQELRVVLKVLDPSHHDIALAFYETASLMSQVSHTHLAFVHGVCVRGPENIMVTEYVEHGPLDVWLRRERGHVPMAWKMVVAQQLASALSYLENKNLVHGNVCGRNILLARLGLAEGTSPFIKLSDPGVGLGALSREERVERIPWLAPECLPGGANSLSTAMDKWGFGATLLEICFDGEAPLQSRSPSEKEHFYQRQHRLPEPSCPQLATLTSQCLTYEPTQRPSFRTILRDLTRLQPHNLADVLTVNPDSPASDPTVFHKRYLKKIRDLGEGHFGKVSLYCYDPTNDGTGEMVAVKALKADCGPQHRSGWKQEIDILRTLYHEHIIKYKGCCEDQGEKSLQLVMEYVPLGSLRDYLPRHSIGLAQLLLFAQQICEGMAYLHAQHYIHRDLAARNVLLDNDRLVKIGDFGLAKAVPEGHEYYRVREDGDSPVFWYAPECLKEYKFYYASDVWSFGVTLYELLTHCDSSQSPPTKFLELIGIAQGQMTVLRLTELLERGERLPRPDKCPCEVYHLMKNCWETEASFRPTFENLIPILKTVHEKYQGQAPSVFSVC |
| 预测分子量 | 110 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TYK2重组蛋白的虚构参考文献示例(内容基于常见研究方向模拟，实际文献请通过学术数据库检索)：
1. **标题**：Expression and Purification of Recombinant Tyk2 Kinase Domain in Escherichia coli
**作者**：Müller, J. et al.
**摘要**：该研究报道了利用大肠杆菌表达系统高效表达人源TYK2激酶结构域的方法，通过亲和层析和尺寸排阻色谱纯化获得高活性重组蛋白，并验证其在体外激酶活性分析中的应用。
2. **标题**：Structural Insights into TYK2 JH2 Pseudokinase Domain Regulation
**作者**：Sundberg, T.B. & Gray, N.S.
**摘要**：通过X射线晶体学解析TYK2假激酶结构域(JH2)的重组蛋白三维结构，揭示其自体抑制机制，为开发针对TYK2的变构抑制剂提供结构基础。
3. **标题**：TYK2 Recombinant Protein-Based Screening Platform for Autoimmune Drug Discovery
**作者**：Chen, X. et al.
**摘要**：建立基于TYK2重组蛋白的高通量筛选体系，评估小分子化合物对JAK-STAT信号通路的抑制效果，成功鉴定出选择性TYK2抑制剂先导化合物。
注：以上为模拟内容，实际文献建议通过PubMed、ScienceDirect等平台以关键词"TYK2 recombinant protein"+"kinase"/"expression"/"structure"等组合检索，重点关注《JBC》《Structure》《Biochemical Journal》等期刊近年发表的研究。
**Background of TYK2 Recombinant Protein**
TYK2 (Tyrosine Kinase 2) is a member of the Janus kinase (JAK) family, a group of non-receptor tyrosine kinases critical for mediating cytokine signaling through the JAK-STAT pathway. Discovered in 1990. TYK2 plays a pivotal role in immune regulation, cell growth, and inflammatory responses by associating with cytokine receptors such as type I interferon, interleukin-12 (IL-12), and IL-23 receptors. Structurally, TYK2 contains four domains: a kinase domain, a pseudokinase domain, and two regulatory SH2-like domains, which collectively enable its activation and downstream signal transduction.
Recombinant TYK2 protein is engineered in vitro using genetic engineering techniques, typically expressed in systems like *E. coli*, insect cells, or mammalian cells to ensure proper folding and post-translational modifications. This recombinant form retains the enzymatic and functional properties of native TYK2. making it indispensable for biochemical studies, drug discovery, and mechanistic research.
Interest in TYK2 has surged due to its therapeutic potential. Dysregulation of TYK2 is linked to autoimmune diseases (e.g., psoriasis, lupus), cancer, and inflammatory disorders. Unlike other JAKs, TYK2’s unique pseudokinase domain offers a selective targeting opportunity, minimizing off-target effects. Recent breakthroughs include the development of TYK2 inhibitors, such as deucravacitinib, which allosterically modulate TYK2 activity and show efficacy in clinical trials for psoriasis and other conditions.
Researchers utilize recombinant TYK2 to study its interaction with substrates, screen inhibitors, and elucidate structural dynamics. Its role in the JAK-STAT pathway also provides insights into immune evasion mechanisms in viral infections and cancer. As precision medicine advances, TYK2 recombinant protein remains a critical tool for unraveling disease mechanisms and developing next-generation therapies.
×
